The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

Chang Liu,Daming Zhou,Rungtiwa Nutalai,Helen M E Duyvesteyn,Aekkachai Tuekprakhon,Helen M Ginn,Wanwisa Dejnirattisai,Piyada Supasa,Alexander J Mentzer,Beibei Wang,James Brett Case,Yuguang Zhao,Donal T Skelly,Rita E Chen,Sile Ann Johnson,Thomas G Ritter,Chris Mason,Tariq Malik,Nigel Temperton,Neil G Paterson,Mark A Williams,David R Hall,Daniel K Clare,Andrew Howe,Philip J R Goulder,Elizabeth E Fry,Michael S Diamond,Juthathip Mongkolsapaya,Jingshan Ren,David I Stuart,Gavin R Screaton

DOI: https://doi.org/10.1016/j.chom.2021.11.013

2022-01-12

Abstract:Alpha-B.1.1.7, Beta-B.1.351, Gamma-P.1, and Delta-B.1.617.2 variants of SARS-CoV-2 express multiple mutations in the spike protein (S). These may alter the antigenic structure of S, causing escape from natural or vaccine-induced immunity. Beta is particularly difficult to neutralize using serum induced by early pandemic SARS-CoV-2 strains and is most antigenically separated from Delta. To understand this, we generated 674 mAbs from Beta-infected individuals and performed a detailed structure-function analysis of the 27 most potent mAbs: one binding the spike N-terminal domain (NTD), the rest the receptor-binding domain (RBD). Two of these RBD-binding mAbs recognize a neutralizing epitope conserved between SARS-CoV-1 and -2, while 18 target mutated residues in Beta: K417N, E484K, and N501Y. There is a major response to N501Y, including a public IgVH4-39 sequence, with E484K and K417N also targeted. Recognition of these key residues underscores why serum from Beta cases poorly neutralizes early pandemic and Delta viruses.